Interstitial Lung Disease Clinical Trials

127 recruitingLast updated: June 17, 2026

There are 127 actively recruiting interstitial lung disease clinical trials across 41 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Kansas City, Kansas, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Interstitial Lung Disease Trials at a Glance

127 actively recruiting trials for interstitial lung disease are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Not Applicable with 30 trials, with the heaviest enrollment activity in New York, Kansas City, and Chicago. Lead sponsors running interstitial lung disease studies include Bastiaan Driehuys, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and United Therapeutics.

Browse interstitial lung disease trials by phase

Treatments under study

About Interstitial Lung Disease Clinical Trials

Looking for clinical trials for Interstitial Lung Disease? There are currently 84 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Interstitial Lung Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Interstitial Lung Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 127 trials

Recruiting

Breathlessness Perceptions Within Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD)BronchiectasisAsthma (Diagnosis)+2 more
University Hospitals, Leicester75 enrolled1 locationNCT07648082
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Not Applicable

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

Chronic Obstructive Pulmonary DiseaseInterstitial Lung DiseaseHypoxemia
State University of New York at Buffalo24 enrolled1 locationNCT07512687
Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary HypertensionPulmonary Hypertension Due to Lung Diseases and Hypoxia
United Therapeutics900 enrolled67 locationsNCT06388421
Recruiting
Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Not Applicable

Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea

Chronic Heart Failure (CHF)DyspneaCancer (With or Without Metastasis)+2 more
University Hospital, Geneva82 enrolled1 locationNCT07173348
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting
Phase 3

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Progressive Pulmonary FibrosisInterstitial Lung Disease
United Therapeutics698 enrolled159 locationsNCT05943535
Recruiting
Phase 2

Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

Fibrotic interstitial lung disease
University of Alberta60 enrolled1 locationNCT06053164
Recruiting
Not Applicable

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Interstitial Lung Disease (ILD)Antisynthetase Syndrome
China-Japan Friendship Hospital80 enrolled1 locationNCT07406932
Recruiting
Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Pulmonary Arterial Hypertension PAHPulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.40 enrolled19 locationsNCT07175038
Recruiting
Phase 3

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Interstitial Lung DiseasePulmonary Hypertension
Insmed Incorporated344 enrolled109 locationsNCT07179380
Recruiting
Not Applicable

Implementation of Home Monitoring in Patients With Pulmonary Fibrosis

Pulmonary FibrosisInterstitial Lung Disease (ILD)
Erasmus Medical Center220 enrolled11 locationsNCT06883448
Recruiting

Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases

Interstitial Lung Disease (ILD)
University of Dundee750 enrolled3 locationsNCT07615504
Recruiting
Not Applicable

Ultrasound and Respiratory Physiological Signals in Lung Diseases

UltrasoundChronic Obstructive Pulmonary DiseaseInterstitial Lung Disease+5 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS25 enrolled1 locationNCT06068647
Recruiting
Not Applicable

Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease

Interstitial Lung Disease
University of British Columbia15 enrolled2 locationsNCT04299945
Recruiting
Not Applicable

Skeletal Muscle Function in Interstitial Lung Disease

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisScleroderma+2 more
University of British Columbia40 enrolled1 locationNCT03800017
Recruiting
Phase 1Phase 2

ADSCs Therapy in Patients With CTD-ILD

Interstitial Lung DiseaseConnective Tissue Diseases
China Medical University Hospital16 enrolled1 locationNCT06574581
Recruiting
Phase 2

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Idiopathic Pulmonary FibrosisPulmonary Fibrosis, Interstitial Lung Disease
Vejle Hospital140 enrolled5 locationsNCT06714123